Tissue Plasminogen Activator and DNase in Empyema REPLY

Tissue Plasminogen Activator and DNase in Empyema REPLY

Bibliographic Details
Main Authors:	Rahman, N, Maskell, N, Nunn, A
Format:	Journal article
Published:	2011

Similar Items

Intrapleural use of tissue plasminogen activator and DNase in pleural infection
by: Rahman, N, et al.
Published: (2011)

Intrapleural use of tissue plasminogen activator and DNase in pleural infection.
by: Rahman, N, et al.
Published: (2011)

Cost-effectiveness of intrapleural use of tissue plasminogen activator and DNase in pleural infection: Evidence from the MIST2 randomised controlled trial.
by: Luengo-Fernandez, R, et al.
Published: (2019)

The biological effect of tissue plasminogen (t-PA) activator and DNase intrapleural delivery in pleural infection patients
by: Kanellakis, N, et al.
Published: (2018)

Biological effect of tissue plasminogen activator (t-PA) and DNase intrapleural delivery in pleural infection patients
by: Kanellakis, N, et al.
Published: (2019)

The biological effect of intrapleural tissue plasminogen (tPA) activator and DNase delivery in pleural infection patients
by: Kanellakis, N, et al.
Published: (2018)

The neurotoxicity of tissue plasminogen activator?
by: Kaur, J, et al.
Published: (2004)

TISSUE PLASMINOGEN-ACTIVATOR VERSUS UROKINASE
by: Ebers, G
Published: (1988)

Urokinase in the treatment of childhood empyema - Author's reply
by: Thomson, A, et al.
Published: (2003)

The authors reply
by: Rahman, N, et al.
Published: (2011)

Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects
by: Al-Hamodi, Z., et al.
Published: (2011)

Effect of plasminogen activator inhibitor-1 and tissue plasminogen activator polymorphisms on susceptibility to type 2 diabetes in malaysian subjects
by: Al-Hamodi, Z., et al.
Published: (2012)

Stroke thrombolysis: is tissue plasminogen activator a defibrillator for the brain?
by: Buchan, A, et al.
Published: (2000)

Ischaemia-reperfusion injury impairs tissue plasminogen activator release in man.
by: Pedersen, C, et al.
Published: (2012)

Management of parapneumonic effusions and empyema.
by: Psallidas, I, et al.
Published: (2014)

ISIS-3 and GISSI-2: no survival advantage with tissue plasminogen activator over streptokinase, but a significant excess of strokes with tissue plasminogen activator in both trials.
by: Collins, R, et al.
Published: (1993)

An immunohistochemical study of the distribution of plasminogen and plasminogen activators in bullous pemphigoid.
by: Venning, V, et al.
Published: (1993)

The dependence of DNase I activity on the conformation of oligodeoxynucleotides.
by: Sutton, D, et al.
Published: (1997)

Phase 1b Trial of LTI-01 (Single Chain Urokinase Plasminogen Activator, scuPA) Intrapleural Fibrinolytic Therapy (IPFT) in Patients with Complicated Parapneumonic Effusions (CPE) or Empyema
by: Idell, S, et al.
Published: (2019)

Exposure of plasminogen and the novel plasminogen receptor, Plg-RKT, on activated human and murine platelets
by: Whyte, CS, et al.
Published: (2020)

Complications associated with recombinant tissue plasminogen activator therapy for acute ischaemic stroke.
by: Balami, J, et al.
Published: (2013)

Ultrasound-enhanced tissue plasminogen activator thrombolysis in an in vitro porcine clot model.
by: Holland, C, et al.
Published: (2008)

The different expressions of urokinasetype plasminogen activator, urokinasetype plasminogen activator receptor, and plasminogen activator inhibitor-1. Several scores of cell pleomorphism, number of mitosis and keratiniza
by: Perpustakaan UGM, i-lib
Published: (2008)

Effectiveness of tissue-type plasminogen activator for acute ischemic stroke: Consequences of protocol violation
by: Karbalai, H, et al.
Published: (1999)

Tissue plasminogen activator antigen and coronary heart disease. Prospective study and meta-analysis.
by: Lowe, G, et al.
Published: (2004)

MK 801 protects tissue plasminogen activator mediated neuroexcitotoxicity in permanent focal ischemia
by: Warren, D, et al.
Published: (2002)

Cost utility analysis of intravenous tissue plasminogen activator in acute ischemic stroke in Canada
by: Demaerschalk, B, et al.
Published: (2003)

Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke.
by: Wang, X, et al.
Published: (2004)

Mannose-binding lectin genotypes: lack of association with susceptibility to thoracic empyema.
by: Chapman, S, et al.
Published: (2010)

The ongoing struggle with empyema management: is surgery really the answer?
by: Bedawi, E, et al.
Published: (2018)

Pediatric parapneumonic empyema, Spain.
by: Obando, I, et al.
Published: (2008)

Genome-wide DNaseI hypersensitive sites profiles in laboratory mouse strains by DNase-seq
by: Hosseini, M
Published: (2013)

The diagnosis and management of pleural empyema.
by: Davies, R, et al.
Published: (1998)

A case of empyema necessitatis.
by: Tonna, I, et al.
Published: (2007)

The diagnosis and management of pleural empyema.
by: Davies, R, et al.
Published: (1998)

Intrapleural fibrinolytic therapy for empyema and pleural loculation: knowns and unknowns
by: Idell, S, et al.
Published: (2018)

Tissue plasminogen activator does not increase neuronal damage in rat models of global and focal ischemia.
by: Klein, G, et al.
Published: (1999)

Lung abscess or empyema? Taking a closer look
by: Hassan, M, et al.
Published: (2018)

Intracameral recombinant tissue plasminogen activator (rtPA) as the primary treatment for secondary pupillary block
by: AR, Siti Noor Atikah, et al.
Published: (2022)

APPEARANCES OF EMPYEMA ON CT: ANALYSIS OF THE MIST 2 COHORT
by: Franklin, J, et al.
Published: (2011)